Informed Consent Form·Notice for Participants

Dear Mr/Ms _____:

You (/ your family) are currently suffering from sepsis, which is a serious and life-threatening disease. You are invited to attend a clinical study of sepsis. Please read the following information as carefully as possible before you decide whether or not to participate in this study. It will help you understand the value and significance, the procedures and duration, as well as the possible benefits, discomfort and risks of participating in this study. If you want, you can also discuss it with your relatives, friends, or consult your doctor to help you make the decision. If you have any question, please do not hesitate to contact the doctor.

1. Background and objective

1.1 Background

Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to infection. Sepsis and septic shock are the leading causes of death in hospitalized patients with expensive medical cost, causing a heavy burden on the public health system. Effective drugs for this worldwide clinical problem are very limited. The dominate treatment strategies are still anti-infection and life support therapy. As a State Category II New Drug manufactured by Tianjin Chase Sun Pharmaceutical Co. Ltd, Xuebijing (XBJ) injection was approved by the China food and drug administration (CFDA) (No. Z20040033) in 2004 for the clinical treatment of sepsis, the approved indications were: for the treatment of infection-induced systemic inflammatory response syndrome (sepsis) and cooperate with the treatment of the damage period in multiple organ dysfunction syndrome. At present, XBJ injection has become one of the featured drugs for treating sepsis in China. In order to further evaluate the efficacy of XBJ injection to improve the outcomes of patients with sepsis, we decided to perform this multicenter, blind, randomized, controlled clinical trial.

1.2 Objective

This study aims to evaluate the efficacy of XBJ injection in treating sepsis and improving the survival rate of sepsis patients.

2. Research method

This study has been approved by the Medical Ethics Committee of Zhongda Hospital Southeast University. This is a multicenter, blind, randomized, controlled clinical trial which will be conducted in more than 40 tertiary general hospitals including Zhongda Hospital Southeast University, and plans to recruit 1800 eligible patients with sepsis to participate voluntarily.

Eligible participants will be randomly assigned to either the XBJ group (XBJ injection combined with routine treatment) or the placebo group (routine treatment combined with 0.9% sodium chloride injection) in a ratio of 1:1. The selection of different groups will not affect the routine treatment for you.

This study will record your personal and disease-related information, including medical history (such as vital signs), routine medical and laboratory examination results (such as blood routine and urine routine tests, fecal occult blood test, hepatic and renal

function, coagulation index, biochemical examination, blood gas analysis, etc.) In order to objectively evaluate the changes of your condition, you will be inquired in detail three times (screening period, the third day after treatment, and the first day after drug stopped) and the changes will be recorded. The outcome at the 28th day after enrollment will also be documented.

The above routine treatment and medical examinations are all necessary for the diagnosis and clinical treatment of sepsis patients. This study does not involve any special examinations or treatment, nor add extra burden on patients.

3. Participants' Responsibility

During the study period, you (/your family) are required to follow the study protocol and undergoing the follow-up by your investigators about your (/your family) outcome.

4. Participants' Rights

You (/your family) are voluntary to participate in this study. You should not feel any pressure to participate. You have the rights to refuse to attend this study, or at any time inform the investigator to request withdrawal from the study without any discrimination or retaliation. Your data will not be included in the study and any medical treatment. Your benefits will not be affected.

You can keep track of the information and progress of this research. If you have any questions about the study, or if you feel any discomfort during the research, or if the study involves your rights, you can always consult the investigators. If you have any complaints, please contact the ethics committee of your hospital.

5. The possible benefits during the study

You, people and society will probably benefit from this study, such as the potential improvement in your condition, and it may be helpful for other patients with similar condition.

Treatment and related medical examinations will be performed according to the routine protocol of sepsis regardless of your participation in this study. Meanwhile, we will provide a 5-day research drugs for the treatment group without any charge. Therefore, participating in this project will not increase you (or your family) additional treatment burden, and the observation and treatment of disease will be more comprehensive and beneficial.

6. The possible benefits and risks during the study, as well as the risk precautions to be taken by the investigators

"A real-world study on adverse drug reactions to Xuebijing injection: hospital intensive monitoring based on 93 hospitals" enrolled 31,913 adverse drug reactions (ADRs) cases in total, and indicated the incidence of ADRs was occasional. The adverse reactions and their incidence (indicated by ‰) stated in the instructions of XBJ injection are as follows:

1) Systemic damage: anaphylactic shock (<0.01‰), shiver (0.06‰), fever (0.16‰), pale, fatigue, sweating, convulsions (0.03‰);

2) Skin damage: skin allergies, rash (0.38‰), itching (0.78‰), skin flushing (0.13‰);

3) Cardiovascular system: palpitations (0.06‰), purpura, elevated or decreased blood pressure, arrhythmia;

4) Nervous system: dizziness (0.06‰), headache (0.09‰);

5) Respiratory system: dyspnea (0.06‰), chest tightness (0.22‰), hernia (0.09‰), anhelation (0.03‰), cough, laryngeal edema (<0.01‰);
6) Digestive system: nausea (0.13‰), vomiting (0.03‰), abdominal pain, diarrhea (0.06‰), abnormal liver function (0.03‰);
7) Urinary system: frequent urination, urgency, dysuria, hematuria;
8) Others: Facial edema, conjunctival hyperemia, abnormal tearing, phlebitis.

The investigators will try to prevent and treat the damage that may result from this study. If any adverse event occurs in this study, the Medical Experts Committee will identify whether it is related to the research drug. If the damage is related to the study, the cost of treatment and relevant economic compensation will be provided according to the provisions of China's "Good Clinical Practice (GCP)".

7. Participants' personal privacy protection

If you (/your family) decide to participate in the study, your personal data in the study are confidential. In all medical records of this study, your name will be replaced by a Pinyin abbreviation. Your medical records and information will be kept in the hospital, only the investigator, research authority department, and ethics committee will be approved to access them. Any public report about the results of this study will not disclose your personal identity.

In addition to this study, it is possible to re-use your medical records and examine specimens when other studies will be performed in the future. You can declare that you are refusing your medical records and specimens be used in research other than this study.

You (/your family) can choose not to attend this study, or to withdraw at any time without any discrimination or retaliation, and your medical treatment and benefits will not be affected.

Your (/your family's) participation in this study is voluntary. You (/your family) can keep track of the relevant information. If you have any questions related to this research, or you have a research-related injury, or have questions about the Participants' rights and interests, you can contact the investigator any time.

In the case of an emergency, please contact the investigator:
Contact phone number:

Participants' informed consent form

I have read the introduction of this trial and have the opportunity to discuss and ask questions with my doctor about this trial. All my questions were answered satisfactorily.

I know the risks and benefits of participating in this trial, and I understand that participating in this trial is voluntary. I inquired about the details of the trial and all the relevant questions were answered. At the same time, my family and I have plenty of time to consider, but also a clear understanding of the following:

1. I can consult my doctor for more information at any time.
2. All my personal information is confidential; my privacy and right to know will be kept confidential.
3. I can withdraw from this trial at any time without discrimination or retaliation, and medical treatment will not be affected.
4. I agree that investigators, research authorities and ethics committees should consult my medical records after approval.
5. I will get a signed and dated copy of the informed consent.

I decided to agree to participate in this trial and try to comply with the doctor's advice.

Participant or legal representative signature: Signature date:
Contact phone number:
The relationship between the signer and the subject:

I confirm that I have accurately explained to the subject the details of the trial, including its rights, possible benefits and risks, and answered all questions.

The participant volunteered to participate in the trial and had given a signed copy of the informed consent.

Investigator signature: Signature date:
Contact phone number: